Thermo Fisher Scientific Allowance for doubtful accounts increased by 1.4% to $149.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 9.7%, from $165.00M to $149.00M. Over 5 years (FY 2020 to FY 2025), Allowance for doubtful accounts shows relatively stable performance with a 1.7% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
An increasing allowance relative to receivables may signal deteriorating customer credit quality or a weakening economic environment.
This is a contra-asset account that represents the estimated portion of accounts receivable that the company does not ex...
Standard accounting practice; peers in similar industrial sectors typically maintain reserves proportional to their credit risk profile.
other_allowance_for_doubtful_accounts_receivable_current| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $135.00M | $138.00M | $150.00M | $170.00M | $177.00M | $185.00M | $189.00M | $190.00M | $180.00M | $184.00M | $193.00M | $197.00M | $202.00M | $204.00M | $173.00M | $165.00M | $160.00M | $155.00M | $147.00M | $149.00M |
| QoQ Change | — | +2.2% | +8.7% | +13.3% | +4.1% | +4.5% | +2.2% | +0.5% | -5.3% | +2.2% | +4.9% | +2.1% | +2.5% | +1.0% | -15.2% | -4.6% | -3.0% | -3.1% | -5.2% | +1.4% |
| YoY Change | — | — | — | — | +31.1% | +34.1% | +26.0% | +11.8% | +1.7% | -0.5% | +2.1% | +3.7% | +12.2% | +10.9% | -10.4% | -16.2% | -20.8% | -24.0% | -15.0% | -9.7% |